China NMPA Drug Inspection - Hubei Zhengguang Jiuzihe Pharmaceutical Co., Ltd. - Stir-fried white peony root

The Shaanxi Provincial Food and Drug Administration (Shaanxi FDA) issued a Drug Quality Announcement on July 24, 2017, publicizing the results of its seventh sampling inspection for the year. The report identified 14 batches of drugs from various manufacturers as non-compliant with established quality standards. Companies implicated included Shaanxi Longli Pharmaceutical Co., Ltd., Xi'an Traditional Chinese Medicine Pieces Factory Co., Ltd., Anhui Fangshi Pharmaceutical Co., Ltd., and several others, primarily located in Shaanxi, Shanxi, Anhui, Sichuan, and Hubei provinces. The main violations detected during these inspections concerned the drugs' physical properties, identification, general quality inspection, and content determination. These findings were assessed against the "Chinese Pharmacopoeia" (various editions), "Shaanxi Provincial Standards for Traditional Chinese Medicine Pieces," and other pertinent national and provincial drug standards, in alignment with the "Drug Administration Law of the People's Republic of China." Following the non-compliance findings, relevant municipal and district food and drug regulatory departments initiated control measures, investigations, and enforcement actions for the affected products and companies. Notably, an initial report of non-compliance for Shiliuwei Xiaoke Capsules from Shanxi Yellow River Pharmaceutical Co., Ltd. (batch 20160601) was later corrected after a retest confirmed its compliance.